Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Capital Expenditures (2020 - 2025)

iSpecimen has reported Capital Expenditures over the past 6 years, most recently at -$999546.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$999546.0 for Q4 2025, down 79.6% from a year ago — trailing twelve months through Dec 2025 was $22410.0 (down 28.96% YoY), and the annual figure for FY2025 was $454.0, down 98.56%.
  • Capital Expenditures for Q4 2025 was -$999546.0 at iSpecimen, down from $999546.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ISPC hit a ceiling of $3.5 million in Q3 2023 and a floor of -$1.5 million in Q2 2023.
  • Median Capital Expenditures over the past 5 years was $339162.0 (2022), compared with a mean of $451807.6.
  • Peak annual rise in Capital Expenditures hit 353.93% in 2023, while the deepest fall reached 448.34% in 2023.
  • iSpecimen's Capital Expenditures stood at -$211984.0 in 2021, then surged by 772.88% to $1.4 million in 2022, then crashed by 81.34% to $266126.0 in 2023, then crashed by 309.13% to -$556547.0 in 2024, then plummeted by 79.6% to -$999546.0 in 2025.
  • The last three reported values for Capital Expenditures were -$999546.0 (Q4 2025), $999546.0 (Q3 2025), and -$556547.0 (Q4 2024) per Business Quant data.